AMYLYX PHARMACEUTICALS ($AMLX) posted quarterly earnings results for Q4 2025 on Tuesday, March 3rd. The company reported earnings of -$0.30 per share, beating estimates of -$0.37 by $0.07. The company also reported revenue of $0, equaling estimates of $0 by $0.
You can see Quiver Quantitative's $AMLX stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
AMYLYX PHARMACEUTICALS Insider Trading Activity
AMYLYX PHARMACEUTICALS insiders have traded $AMLX stock on the open market 14 times in the past 6 months. Of those trades, 1 have been purchases and 13 have been sales.
Here’s a breakdown of recent trading of $AMLX stock by insiders over the last 6 months:
- JOSHUA B COHEN (Co-Chief Executive Officer) has made 0 purchases and 4 sales selling 161,382 shares for an estimated $2,191,282.
- JUSTIN B. KLEE (Co-Chief Executive Officer) has made 0 purchases and 4 sales selling 161,403 shares for an estimated $2,190,776.
- KAREN FIRESTONE purchased 8,100 shares for an estimated $100,845
- GINA MAZZARIELLO (Chief Legal Officer) has made 0 purchases and 2 sales selling 6,867 shares for an estimated $98,867.
- CAMILLE L BEDROSIAN (Chief Medical Officer) sold 6,580 shares for an estimated $94,418
- JAMES M FRATES (Chief Financial Officer) has made 0 purchases and 2 sales selling 6,883 shares for an estimated $89,050.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
AMYLYX PHARMACEUTICALS Hedge Fund Activity
We have seen 110 institutional investors add shares of AMYLYX PHARMACEUTICALS stock to their portfolio, and 83 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FMR LLC added 5,139,212 shares (+45.2%) to their portfolio in Q4 2025, for an estimated $62,081,680
- POINT72 ASSET MANAGEMENT, L.P. removed 2,455,066 shares (-88.0%) from their portfolio in Q4 2025, for an estimated $29,657,197
- ADAGE CAPITAL PARTNERS GP, L.L.C. removed 1,983,172 shares (-22.5%) from their portfolio in Q3 2025, for an estimated $26,951,307
- JANUS HENDERSON GROUP PLC added 1,929,639 shares (+76.1%) to their portfolio in Q4 2025, for an estimated $23,310,039
- BLACKROCK, INC. added 1,913,739 shares (+26.8%) to their portfolio in Q4 2025, for an estimated $23,117,967
- PARADIGM BIOCAPITAL ADVISORS LP removed 1,900,000 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $22,952,000
- COMMODORE CAPITAL LP added 1,574,522 shares (+38.6%) to their portfolio in Q4 2025, for an estimated $19,020,225
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
AMYLYX PHARMACEUTICALS Analyst Ratings
Wall Street analysts have issued reports on $AMLX in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Stifel issued a "Buy" rating on 03/03/2026
- HC Wainwright & Co. issued a "Buy" rating on 11/07/2025
- Goldman Sachs issued a "Buy" rating on 09/16/2025
- Guggenheim issued a "Buy" rating on 09/15/2025
To track analyst ratings and price targets for AMYLYX PHARMACEUTICALS, check out Quiver Quantitative's $AMLX forecast page.
AMYLYX PHARMACEUTICALS Price Targets
Multiple analysts have issued price targets for $AMLX recently. We have seen 8 analysts offer price targets for $AMLX in the last 6 months, with a median target of $20.0.
Here are some recent targets:
- James Condulis from Stifel set a target price of $21.0 on 03/03/2026
- Geoff Meacham from B of A Securities set a target price of $19.0 on 02/20/2026
- Andrew S. Fein from HC Wainwright & Co. set a target price of $28.0 on 02/10/2026
- Geoff Meacham from Citigroup set a target price of $20.0 on 10/17/2025
- Joel Beatty from Baird set a target price of $19.0 on 10/16/2025
- Corinne Johnson from Goldman Sachs set a target price of $20.0 on 09/16/2025
- Seamus Fernandez from Guggenheim set a target price of $25.0 on 09/15/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
